Source link : https://newshealth.biz/health-news/ema-greenlights-voranigo-for-idh-mutant-grade-2-glioma/
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization in the European Union to Voranigo (vorasidenib; Les Laboratoires Servier), for treatment of predominantly nonenhancing grade 2 astrocytoma or oligodendroglioma with specific mutations. The treatment is intended for adults and adolescents aged 12 years or older, weighing […]
The post EMA Greenlights Voranigo for IDH-Mutant Grade 2 Glioma first appeared on News Health.
—-
Author : News Health
Publish date : 2025-07-28 13:29:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8